The All.Can initiative, for which HPP acts as secretariat, has revealed the first findings from its patient survey at an event at the UK Parliament.
All.Can UK, a national initiative connected with the international All.Can group, became the first country to reveal findings from the All.Can patient survey.
The survey, which ran throughout 2018, sought patients’ and carers’ perspectives on inefficiencies in cancer care. The UK findings were presented at the Britain Against Cancer conference, on 4 December 2018, hosted by the All-Party Parliamentary Group on Cancer.
Key findings from the UK included:
- Two in five people with cancer had been initially diagnosed with something else – sometimes on multiple occasions
- One in five people had to wait more than six months for a cancer diagnosis
- 34% of respondents said they were given too much medication and had excess amounts at the end of their treatment.
The survey findings gained coverage in the UK media, with reports in the Independent, The Sun and Pharma Times.
All.Can worked with Quality Health to develop the patient survey. Quality Health was responsible for all aspects of survey administration and data analysis, with input from All.Can national initiatives and the international research and evidence working group.
The UK piloted the All.Can patient survey ahead of roll-out in other countries throughout 2018. The survey closed in the UK in August but continued running until 30 November in Australia, Belgium, Canada, France, Italy, Poland, Spain and Sweden. There was also an international version for people whose countries were not individually represented. Data from these surveys are now being analysed. All.Can will publish a report of the findings from all countries in early 2019.
